### **Text Searchable Document**

### Data Evaluation Report on the Reproductive Effects of AE 0172747 Technical on Mallard nek (Ange platurhynchae)

PMRA Submission	• •	· ·	EPA MRID Number 466955-05
Data Requireme	ent:	PMRA Data Code EPA DP Barcode OECD Data Point EPA MRID EPA Guideline	{} D325337 {
Test material: Common name	AE 0172747 AE 0172747		<b>Purity:</b> 94.0%
Chemical name:		2-[2-Chloro-4-mesyl-3-((2,2,	2-trifluoroethoxy)methyl)benzoyl]cyclohexane-1,3-dioneyl)-3-[(2,2,2-trifluoroethoxy)methyl]-benzoyl]-1,3-
Primary Review Staff Scientist, I			Signature: Christic E. Padove Date: 6/2/06
Secondary Revi Senior Scientist		. Myers Environmental Inc.	Signature: Jeu'S Mym  Date: 6/12/06
Primary Review EPA/OPP/EFEI			Date: {}
Secondary Revi {EPA/OECD/PI		nnette Martinez	Date: 7/14/06
Reference/Subn	nission No.:	{}	_
Company Code	<b>{</b>	} [For PMRA]	

**Active Code** [For PMRA] {.....} Use Site Category: {......} [For PMRA] EPA PC Code 012801

Date Evaluation Completed: XX-XX-XXXX

<u>CITATION</u>: Frey, LT., et al. 2004. AE 0172747; Substance Technical; Product Code: AE 0172747 00 1C94 0002: A Reproduction Study with the Mallard. Unpublished study performed by Wildlife International Ltd., Easton, MD. Laboratory Project No. 149-194. Study submitted by Bayer CropScience GmbH, Frankfurt am Main, Germany. Study initiated April 29, 2003 and submitted June 2, 2004.

**DISCLAIMER:** This document provides guidance for EPA and PMRA reviewers on how to complete a data evaluation record after reviewing a scientific study concerning the reproductive effects of a pesticide on avian species. It is not intended to prescribe conditions to any external party for conducting this study nor to establish absolute criteria regarding the assessment of whether the study is scientifically sound and whether the study satisfies any applicable data requirements. Reviewers are expected to review and to determine for each study, on a case-bycase basis, whether it is scientifically sound and provides sufficient information to satisfy applicable data requirements. Studies that fail to meet any of the conditions may be accepted, if appropriate; similarly, studies that meet all of the conditions may be rejected, if appropriate. In sum, the reviewer is to take into account the totality of factors related to the test methodology and results in determining the acceptability of the study.



PMRA Submission Number {.....}

EPA MRID Number 466955-05

### **EXECUTIVE SUMMARY**

The one-generation reproductive toxicity of AE 0172747 Technical to 16 pairs per level of 21-week old mallard duck (*Anas platyrhynchos*) was assessed over approximately 20 weeks. AE 0172747 Technical was administered to the birds in the diet at nominal concentrations of 0 (vehicle control), 63, 250, and 1000 mg ai/kg dw diet. Mean-measured concentrations were <10 (<LOD, control), 65.3, 260, and 1030 mg ai/kg diet, respectively. The NOAEC could not be determined in this study (<65.3 mg ai/kg diet) due to statistically significant reductions in adult male weight gain and several reproductive endpoints (ratios of number hatched to eggs laid and eggs set and the ratio of survivors to eggs set) at all treatment levels.

Additionally, there were numerous adverse effects on adult and reproductive parameters at the highest treatment level (1030 mg ai/kg diet). These included (% reduction from control): female weight gain (81%), eggs laid (24%), eggs set (28%), the ratio of eggs set to eggs laid (8%), viable embryos (34%), live embryos (34%), number hatched (38%), 14-day-old survivors (43%), the ratio of survivors to number hatched (12%), and hatchling and survivor body weights (5 and 10%).

At the 1030 mg ai/kg diet level, a single treatment-related mortality occurred during Week 4, and a thin appearance was observed in nine adult birds. There was no effect on overall food consumption and amounts increased with higher concentrations.

This study is scientifically sound. However, adequate frozen storage stability data were not provided and a NOAEC was not determined due to significant adverse effects on several adult and reproductive endpoints at all treatment levels. As a result, this study is classified as SUPPLEMENTAL, and it does not satisfy the guideline requirement for a mallard duck (*Anas platyrhynchos*) reproductive toxicity study.

### **Results Synopsis**

Test Organism Size/Age(mean Weight): 21-weeks old; 925-1396 g (combined sexes)

NOAEC: <65.3 mg ai/kg diet LOAEC: 65.3 mg ai/kg diet

Endpoint(s) Affected: adult male and female weight gain, eggs laid, eggs set, the ratio of eggs set to eggs laid, viable embryos, live embryos, number hatched, the ratios of number hatched to eggs laid and eggs set, 14-day-old survivors, the ratios of survivors to eggs set and number hatched, and hatchling and survivor body weights.

Most sensitive endpoint: adult male body weight gain, the ratios of number hatched to eggs laid and eggs set and the ratio of survivors to eggs set

PMRA Submission Number {......}

EPA MRID Number 466955-05

### I. MATERIALS AND METHODS

**GUIDELINE FOLLOWED:** 

The study protocol was based on procedures outlined in the U.S. EPA *Pesticide Assessment Guidelines*, §71-4; the U.S. EPA Ecological Effects Test Guideline OPPTS No. 850.2300; the OECD Guideline No. 206; and ASTM Standard E1062-86. Deviations from OPPTS 850.2300 included:

- 1. Adult birds were younger (21 weeks) at test initiation than recommended (≥28 weeks).
- 2. Mortality of the adult birds during acclimation was not reported.
- 3. Pen floor size was significantly less (3375 cm²/duck) than recommended (at least 10,000 cm²/duck). As cages were much smaller than recommended, documentation that reproductive parameters and health of birds are not adversely affected should be provided. THIS AFFECTS THE VALIDITY OF THE STUDY.
- 4. Pre-laying exposure of birds was 8 weeks instead of the recommended 10 weeks minimum. THIS AFFECTS THE VALIDITY OF THE STUDY.
- 5. The actual or expected field residue level was not reported, so it was unknown if the concentration range included this level.
- 6. It was not reported if the acetone used in preparing the treated feed was allowed to completely evaporate prior to offering.
- 7. Although adequate ambient 7-day feeder trough stability was demonstrated, frozen storage stability data were not generated. Premix batches were prepared every 3-4 weeks, and stored frozen in plastic bags until needed. THIS AFFECTS THE VALIDITY OF THE STUDY
- 8. It was unclear if a brooder temperature gradient was provided for the hatchlings.
- 9. Clinical effects of hatchlings, if observed, were not reported.
- 10. Significant adverse effects were detected at all treatment levels for adult male body weight gain and several reproductive endpoints (ratios of number hatched to eggs laid and eggs set and the ratio of survivors to eggs set); therefore, a NOAEC was not determined in this study. THIS AFFECTS THE VALIDITY OF THE STUDY.

**COMPLIANCE:** Signed and dated GLP, Quality Assurance and Data Confidentiality

statements were provided.

A. MATERIALS:

1. Test Material

AE 0172747 Technical

**Description:** 

Beige powder

Lot No./Batch No.:

OP 2250027 / PFI 0215

Purity:

94.0%

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Stability of compound under test conditions:

Stability was verified at all treatment levels under actual use conditions. Samples were assessed after 7 days of ambient feeder storage during Week 1. Recoveries were 96.9-102% of initial measured concentrations.

(OECD recommends water solubility, stability in water and light, pKa, Pow, and vapor pressure of test compound)

Storage conditions of

test chemicals:

Ambient conditions

Physicochemical properties of AE 0172747 Technical.

Parameter	Values	Comments
Water solubility at 20°C	Not reported	
Vapor pressure	Not reported	
UV absorption	Not reported	
pKa	Not reported	
Kow	Not reported	

### 2. Test organism:

Table 1: Test organism.

Parameter	Details	Remarks
r arumeter	Details	Criteria
Species (common and scientific names):	Mallard duck (Anas platyrhynchos)	Birds were from the same hatch, and were phenotypically indistinguishable from wild birds.
		Recommended species include a wild waterfowl species, preferably the mallard (Anas platyrhynchos) or an upland game species, preferably the northern bobwhite (Colinus virginianus)
Age at Study Initiation:	21 weeks old	It was stated that birds were approaching their first breeding season. Test birds should be at least 7 months (28 weeks) old.
		Birds approaching their first breeding season should be used.
Body Weight: (mean and range)	Males: Overall range (n=64) 946 to 1396 g, with group means of 1185 to 1188 g.	Body weights were recorded at weeks 0, 2, 4, 6, 8, and 20 (adult termination).

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Parameter	Details	Remarks
1 al ametei	Details	Criteria
	Females: Overall range (n=64) of 925 to 1335 g, with group means of 1075 to 1133 g.	Body weights should be recorded at test initiation and at biweekly intervals up to week eight or up to the onset of egg laying and at termination.
Source:	Whistling Wings, Inc. 113 Washington Street Hanover, IL	All birds should be from the same source.

### **B. STUDY DESIGN:**

### 1. Experimental Conditions

a. Range-finding study: A 6-week exposure pilot study (Wildlife International Project No. 149-188) was conducted during the egg-laying phase of the reproductive cycle of mallard. Nominal dietary concentrations were 0, 130, 320, and 800 mg ai/kg diet. Endpoints assessed included health, weight gain, and feed consumption of adults as well as egg production and egg weights. Compound-related effects on body weight and necropsy results were noted in birds at the 800 mg ai/kg diet level, and upon feed consumption and egg production at the 320 and 800 mg ai/kg diet levels. No compound-related effects were observed at the 130 mg ai/kg diet level.

### b. Definitive Study

Table 2: Experimental Parameters.

Parameter	Details	Remarks
		Criteria
Acclimation period:	5 weeks	The study author reported that at test initiation, all birds were
Conditions (same as test or not):	Same as test	examined for physical injuries and general health, and that birds
Feeding:	Wildlife International Ltd. Game Bird Ration formulated by Agway Inc. and tap water were provided ad libitum.	that did not appear healthy, either due to injury or inability to acclimate to laboratory conditions, or were outside the desired weight range for the test,
Health (any mortality observed):	Mortality not reported.	were excluded from the study.  During acclimation, birds received 8 hours light/day.

PMRA Submission Number {.....}

Parameter	Details	Remarks
		Criteria
		Recommended observation period includes a 2-3 week health observation period prior to selection of birds for treatment. Generally, birds should be healthy without excess mortality. Feeding should be ad libitum, and sickness, injuries or mortality should be noted.

### Data Evaluation Report on the Reproductive Effects of AE 0172747 Technical on Mallard **Duck** (*Anas platyrhynchos*) PMRA Submission Number {.....}

Parameter	Details	Remarks
1 arameter	Details	Criteria
Test duration pre-laying exposure: egg-laying exposure: withdrawal period, if used:	8 weeks Approx. 12 weeks N/A	Egg laying commenced upon photostimulation.  Recommended pre-laying exposure duration: At least 10 weeks prior to the onset of egg-laying. Recommended exposure duration with egg-laying: At least 10 weeks. Recommended withdrawal period: If reduced reproduction is evident, a withdrawal period of up to 3 weeks should be added to the test phase.
Pen (for parental and offspring) size:	Parents (one pair) were housed in battery cages measuring 75 x 90 x 45 cm high. Offspring (by set and group) were housed in 62 x 92 x 25.5 cm high battery brooders.	Pen floor size was significantly less (3375 cm²/duck) than recommended (at least 10,000 cm²/duck). As cages were much smaller than recommended, documentation that reproductive parameters and health of birds are not adversely affected should be
number:	Parental and offspring pens were constructed of vinyl-coated wire mesh.  16 parental pens/treatment level. Hatchlings were group-housed according to the appropriate parental concentration.	Pens Pens should have adequate room and be arranged to prevent crosscontamination.  Materials Recommended materials include nontoxic material and nonbinding material, such as galvanized steel.  Number At least 5 replicate pens should be used for mallards housed in groups of 7. For other arrangements, at least 12 pens should be used, but considerably more may be used if birds are kept in pairs. Chicks should be housed according to parental grouping.
Number of birds per pen (male:female)	2 birds/pen (1 male:1 female)	One male and one female per pen should be used. For quail, one male and two females should be used. For ducks, two males and five females should be used.

### Data Evaluation Report on the Reproductive Effects of AE 0172747 Technical on Mallard Duck (Anas platyrhynchos) PMRA Submission Number {.....}

Parameter	Details	Remarks
- w,		Criteria
Number of pens per group/treatment negative control: solvent control: treated:	N/A 16 pens 16 pens/treatment	At least 12-16 pens should be used, but considerably more if birds are kept in pairs.
Test concentrations (mg ai/kg diet) nominal: measured:	0 (vehicle control), 63, 250, and 1000 mg ai/kg diet <10 ( <lod, 1030="" 260,="" 65.3,="" ai="" and="" control),="" diet<="" kg="" mg="" td=""><td>Dietary concentrations were adjusted for purity of the test substance. Measured concentrations were determined at all levels during Weeks 2, 3, 4, 8, 12, 16, and 20. Mean-measured concentrations had coefficients of variation of approximately 4% indicating relative precision among the samples.  Recommended test concentrations include at least two concentrations other than the control; three or more will provide a better statistical analysis. The highest test concentrations should show a significant effect or be at or above the actual or expected field residue level.</td></lod,>	Dietary concentrations were adjusted for purity of the test substance. Measured concentrations were determined at all levels during Weeks 2, 3, 4, 8, 12, 16, and 20. Mean-measured concentrations had coefficients of variation of approximately 4% indicating relative precision among the samples.  Recommended test concentrations include at least two concentrations other than the control; three or more will provide a better statistical analysis. The highest test concentrations should show a significant effect or be at or above the actual or expected field residue level.
Maximum labeled field residue anticipated and source of information:	Not reported	The highest test concentrations should show a significant effect or be at or above the actual or expected field residue level. The source (i.e., maximum label rate in lb ai/A and ppm), label registration no label date, and site should be cited]
Solvent/vehicle, if used type: amount:	Acetone and corn oil Approx. 1.6 and 0.8%, respectively (v:w)	Recommended solvents include corn oil or other appropriate vehicle not more than 2% of diet by weight

PMRA Submission Number {.....}

Parameter	Details	Remarks
1 at ameter	Details	Criteria
Was detailed description and nutrient analysis of the basal diet provided? (Yes/No)	Yes. The basal ration contained at least 27% protein and 2.5% fat, and no more than 5% fiber. The diet was supplemented with	Offspring were fed basal ration without the addition of limestone.  A commercial breeder feed or an equivalent that is appropriate for the test species is recommended.
	limestone, to increase the calcium level to approximately 3%.	
Preparation of test diet	material was dissolved in acetone and corn oil using a magnetic stir plate, and quantitatively transferred to a bowl containing a portion of basal feed. The contents of the bowl were mixed on a Hobart mixer for approximately 15 minutes. The	It was not reported if the acetone (350 ml per premix) was allowed to completely evaporate prior to offering.
		A premixed diet containing the test substance should be mechanically mixed with basal diet. If an evaporative vehicle is used, it should be completely evaporated prior to feeding.
	As needed, the appropriate premix was combined with additional basal ration and limestone and mixed in a Patterson-Kelly Twin Shell Blender for approximately 20 minutes.	
Indicate whether stability and homogeneity of test material in diet determined (Yes/No)	Yes	
Were concentrations in diet verified by chemical analysis?	Yes	

PMRA Submission Number {.....}

Parameter	Details	Remarks
Tarameter	Details	Criteria
Did chemical analysis confirm that diet was stable and homogeneous?	Yes, for ambient 7-day feeder storage. Frozen storage stability data were not generated (premix batches were prepared every 3 to 4 weeks and were stored frozen until needed).	Stability was assessed in treated feed prepared at all treatment levels after 7 days of ambient feeder storage during Week 1. Recoveries averaged 98.0, 96.9, and 102% of initial concentrations for the 63, 250, and 1000 mg ai/kg diet levels, respectively.
	Yes	Homogeneity was assessed in treated feed prepared on Day 0 of Week 1 at all test levels. Six samples per level were collected: one sample per side from the top, middle, and bottom of the batch. Calculated coefficients of variations (CV=RSD) were 3.36, 6.12, and 4.18% for the 63, 250, and 1000 mg ai/kg diets, respectively.
Feeding and husbandry	Feeding and husbandry conditions appeared to be adequate, given guideline recommendations.	
Test conditions (pre-laying) temperature: relative humidity: photoperiod:	24.1 ± 1.5°C 70 ± 9% 8 hr light/day up through Week 8; 17 hr light/day thereafter.	Temperature and humidity were for the adult room during the entire study. The air handling system provided up to 15 room air volumes every hours.  Light intensity averaged approximately 211 lux (or 20 foot
		candles).  Recommended temperature: about 21°C (70°F) Recommended relative humidity: about 55% Recommended lighting First 8 weeks: 7 h per day. Thereafter: 16-17 h per day. At least 6 foot-candles are recommended at bird level.

PMRA Submission Number {.....}

Parameter	Details	Remarks
1 avainetti	Details	Criteria
Egg Collection and Incubation		
Egg collection and storage collection interval: storage temperature: storage humidity:	Daily 13.5 ± 0.7°C 87 ± 7%	To reduce the possibility of pathogen contamination, the collected eggs were washed in a commercial egg washer (Kuhl) with a chlorine-based detergent at 45°C for approximately 3 minutes. The eggs were allowed to cool to ambient temperature and rinsed with fresh water prior to storage.
		Eggs should be collected daily; recommended egg storage temperature is approximately 16°C (61°F); recommended humidity is approximately 65%. Recommended collection interval: daily
Were eggs candled for cracks prior to setting for incubation?	Yes	Eggs should be candled on day 0
Were eggs set weekly?	Yes	
When candling was done for fertility?	Eggs were candled again on Days 14 (embryo viability) and 21 (embryo survival).	Quail: approx. day 11 Ducks: approx. day 14
When the eggs were transferred to the hatcher?	Day 24	Bobwhite: usually day 21 Mallard: usually day 23
Hatching conditions temperature:	Petersime Hatcher: 37.2 ± 0.0°C NatureForm incubator: 37.4 ± 0.0°C	Recommended temperature is 39°C (102°F) Recommended humidity is 70%
humidity:	Petersime Hatcher: approx. 77% NatureForm incubator: approx. 58%	
photoperiod:	16 hours light/8 hours dark (hatchlings)	

PMRA Submission Number {......}

Parameter	Details	Remarks  Criteria
Day the hatched eggs were removed and counted	Day 27 or 28	The temperature of the brooding compartment (during the 14-day post-hatch period) was approximately 38°C. It is recommended that a temperature gradient in the pen of approximately 22 to 35°C is provided to allow the hatchlings to seek a proper temperature.
		Eggs for bobwhite should be removed on day 24; for mallard on day 27
Were egg shells washed and dried for at least 48 hrs before measuring?	Yes	
Egg shell thickness no. of eggs used:	One egg was collected (when available) from each odd numbered cage during odd numbered weeks and from each even numbered cage during the even numbered weeks.	Newly hatched eggs should be collected at least once every two weeks. Thickness of the shell plus membrane should be measured to the nearest 0.01 mm with 3 - 4 measurements per shell.
intervals:	Once weekly throughout the egg laying period.	
mode of measurement:	Five points around the equatorial circumference were measured to the nearest 0.002 mm.	
Reference chemical, if used	None used	

#### 2. Observations:

Table 3: Observations.

Parameter	Details	Remarks
Parameters measured		
Parental (mortality, body weight, mean feed consumption)	- mortality - body weight	All adult birds were subjected to gross necropsy.
Egg collection and subsequent development (no. of eggs laid, no. of eggs cracked, shell thickness, no. of eggs set, no. of viable embryos, no. of live 3 week embryos, no. hatched, no. of 14-day survivors, average weight of 14-d old survivors, mortality, gross pathology, others)	- food consumption - signs of toxicity - necropsy  - eggs laid - eggs cracked - egg shell thickness - eggs set - viable embryos - live 3-week embryos - number of hatchlings - hatchling body weight - number of 14-day-old survivors - 14-day-old survivor body weight - signs of toxicity of hatchlings	Recommended endpoints measured include:  • Eggs laid/pen • Eggs set/pen • Viable embryos/pen • Live 3-week embryos/pen • Normal hatchlings/pen • 14-day-old survivors/pen • 14-day-old survivors/pen • Weights of 14-day-old • survivors (mean per pen) • Egg shell thickness • Food consumption (mean per pen) • Initial and final body weight (mean per pen)
Indicate if the test material was regurgitated	No indications of dietary regurgitation.	
Observation intervals (for various parameters)	Parental and hatchling mortality and parental signs of toxicity were recorded once daily. Parental body weights were recorded at weeks 0 (test initiation), 2, 4, 6, 8, and 20 (adult termination). Parental food consumption was measured weekly throughout the test.	Body weights and food consumption should be measured at least biweekly
Were raw data included?	Yes	

### **II. RESULTS AND DISCUSSION:**

### A. MORTALITY:

No mortalities were observed in either the 63 or 250 mg ai/kg diet groups. However, one incidental mortality occurred in the control group, and one treatment-related mortality occurred in the 1000 mg ai/kg diet treatment group.

The single control mortality was a female (pen 813) that was found dead during Week 20; foot lesions were noted prior to death. Necropsy findings included lesions on both feed, autolysis throughout the abdominal cavity

PMRA Submission Number {.....}

EPA MRID Number 466955-05

with lesions consistent with egg-yolk peritonitis, pale kidneys, enlarged spleen, observation of cystic follicles, and a regressing ovary. Necropsy of the pen-mate was unremarkable.

The single mortality in the 1000 mg ai/kg diet level was a male (pen 851) that was euthanized due to a debilitated condition during Week 4. Clinical effects noted prior to death included reduced reaction to external stimuli and ataxia. At necropsy the bird was noted as emaciated, with a loss of muscle mass and prominent keel. In addition, the spleen and kidneys were pale. Gastrointestinal findings included an empty proventriculus and primarily-empty gizzard, and pasty cecal contents. Necropsy of the pen-mate showed foot lesions and a regressed ovary, but was otherwise unremarkable.

Due to the nature of the lesions observed at necropsy of the single decedent bird from the 1000 mg ai/kg diet level, and the lack of lesions indicative of an incidental cause of death, a treatment-related effect could not be precluded. Given the correlation of the mortality with the weight loss and reduced feed consumption observed at this level (see below), it was concluded that the mortality was treatment-related. The NOAEC for adult mortality was therefore 250 mg ai/kg diet.

Table 4: Effect of AE 0172747 Technical on Mortality of Mallard Duck.

Treatment	Observation Period								
(mg ai/kg diet) Mean-measured (and Nominal)	V	Veek 7	W	eek 14	V	Week 20			
Concentrations	No Male	o. Dead Female	No. Dead Male Female		No. Dead Male Female				
Control	0	0	0	0	0	1			
65.3 (63)	0	0	0	0	0	0			
260 (250)	0	0	0	0	0	0			
1030 (1000)	1	0	1	0	1	0			

#### B. REPRODUCTIVE AND OTHER ENDPOINTS:

Abnormal Effects/Behavior: No overt signs of toxicity were observed in birds from the 63 or 250 mg ai/kg diet levels. However, nine birds in the 1000 mg ai/kg diet level were noted to have a thin appearance (streamlined, lacking body width, less breast muscle mass apparent, keel evident). Since the observation correlates with the body weight loss observed in this group, this observation was considered to be treatment-related. Incidental clinical observations noted in the control group and all treatment groups during the test included those normally associated with injuries and pen wear; effects included foot lesions, feather loss, and dyspnea. The NOAEC for clinical signs of toxicity was 250 mg ai/kg diet.

Food Consumption: No apparent treatment-related effects on feed consumption were observed in birds from the 63 or 250 mg ai/kg diet levels. Although there was a statistically-significant increase (of 131% of control value) in feed consumption during Week 4 at the 250 mg ai/kg diet level, the difference was transient and not considered to be treatment-related. Treatment-related effects in food consumption were observed at the 1000 mg ai/kg diet level; statistically-significant decreases in consumption were observed during Weeks 1 (50%) and 2 (39%) at p<0.01. Statistically-significant increases in food consumption (perhaps compensatory) were then observed during Weeks 5 (136%), 6 (134%), and 18 (131%) at p<0.01 and during Weeks 19 (132%) and 20 (130%) at p<0.05. The NOAEC for feed consumption was 250 mg ai/kg diet.

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Body Weight: No apparent treatment-related effects on body weight were observed in males or females at the 63 mg ai/kg diet level, or in males at the 250 mg ai/kg diet level. In females from the 250 mg ai/kg diet level, statistically-significant treatment-related reductions in body weight (of 10%, p<0.05) were noted at Weeks 2 and 4. No other statistically-significant differences were observed in females from this level. At the 1000 mg ai/kg diet level, statistically-significant reductions in the body weights of males were observed at Weeks 2 (14%, p<0.01) and 4 (10%, p<0.05) compared to the control. In females from this level, statistically-significant reductions (ranging from 19 to 10%, p<0.01) were observed at Weeks 2, 4, 6 and 20 (termination). The subsequent NOAEC for adult body weight was 63 mg ai/kg diet.

Necropsy: There were no macroscopic findings at necropsy that were considered related to treatment.

Reproductive Effects: No statistically-significant differences from controls were observed by the study author on any reproductive parameter for the 63 and 250 mg ai/kg diet levels. Although not statistically-significant, there was a decrease in hatchability (hatchlings as a percentage of live 3-week embryos) at the 250 mg ai/kg diet level (68 versus 83% for the control). It was noted that this decrease was primarily influenced by data from one pen (Pen 844) from which none of the 32 live 3-week embryos hatched.

At the 1000 mg ai/kg diet level, there were treatment-related reductions in several reproductive parameters. Although not statistically-significant, there were slight decreases in egg production (eggs laid as a percentage of the maximum laid; 44 versus 55% for the control), viable embryos (viable embryos as a percentage of eggs set; 89 versus 95%), and hatchability (hatchlings as a percentage of live 3-week embryos, 73 versus 83%). In addition, a statistically-significant reduction in offspring survival (14-day old survivors as a percentage of hatchlings; 87 versus 99%, p<0.01) was observed. Additionally, there were statistically-significant reductions in hatchlings as a percentage of the maximum number of eggs set (28 versus 46%, p<0.01), 14-day old survivors as a percentage of eggs set (58 versus 77%, p<0.05), and 14-day old survivors as a percentage of maximum set (26 versus 45%, p<0.01).

No treatment-related differences in egg shell thickness or hatchling body weights were observed at any treatment level by the study author. However, the body weight of 14-day old survivors was statistically-reduced (10%, p<0.01) at the 1000 mg ai/kg diet level. Clinical effects of hatchlings, if observed, were not reported. Based on treatment-related reductions in various reproductive parameters at the 1000 mg ai/kg diet level, the NOAEC for reproductive endpoints was 250 mg ai/kg diet.

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Table 5: Reproductive and Other Parameters (nominal concentrations; study author-reported).

Parameter	Control	63 mg ai/kg	250 mg ai/kg	1000 mg ai/kg	NOAEC/ LOAEC
Eggs laid/pen	47	54	49	36	N/A
Eggs laid/hen/day	0.56	0.64	0.58	0.43	N/A
Eggs cracked	3	8	5	14	N/A
Eggs set	635	769	704	456	N/A
Shell thickness (mm ± SD)	$0.395 \pm 0.019$	$0.397 \pm 0.021$	$0.393 \pm 0.019$	$0.382 \pm 0.021$	1000 mg ai/kg >1000 mg ai/kg
Viable embryos	604	723	682	401	N/A
Live 3-week embryos	600	720	675	397	N/A
No. of hatchlings/hen <sup>(a)</sup>	33.0	36.0	29.5	20.4	N/A
No. of normal hatchlings	496	577	472 306		N/A
Hatchling weight (g ± SD)	32 ± 2	34 ± 2	31 ± 2	31 ± 2	1000 mg ai/kg >1000 mg ai/kg
14-day old survivors	490	570	463	280	N/A
14-day old survivors weight (g ± SD)	313 ± 27	306 ± 15	$302 \pm 26$	281 ± 22**	250 mg ai/kg 1000 mg ai/kg
Mean food consumption (g/bird/day) (a)	154	168	175	188	250 mg ai/kg 1000 mg ai/kg
Weight (g) of parent females at test initiation: at onset of egg laying: at test termination:	1133 1080 1221	1118 1035 1178	1098 1018 1187	1075 1015 1095**	63 mg ai/kg 250 mg ai/kg
Weight (g) of parent males at test initiation: at onset of egg laying: at test termination:	1187 1122 1175	1188 1067 1132	1185 1117 1124	1187 1079 1101	250 mg ai/kg 1000 mg ai/kg
Gross pathology	No treatment-re	1000 mg ai/kg >1000 mg ai/kg			

N/A = Not statistically-analyzed.

<sup>(</sup>a) Reviewer-calculated.

<sup>\*\*</sup> Statistically different from the control at p<0.01.

PMRA Submission Number {.....}

EPA MRID Number 466955-05

#### C. REPORTED STATISTICS:

The following variables were statistically analyzed: adult body weight, adult feed consumption, eggs laid of maximum laid, eggs cracked of eggs laid, viable embryos of eggs set, live 3-week embryos of viable embryos, hatchlings of live 3-week embryos, 14-day old survivors of hatchlings of eggs set, 14-day old survivors of eggs set, hatchlings of maximum set, 14-day old survivors of maximum set, egg shell thickness, and offspring's body weight (0 and 14 days).

Each of the treatment groups was compared to the control group using an analysis of variance (ANOVA) followed by Dunnett's Multiple Comparison Procedure. Sample units were the individual pens within each experimental group, except adult body weights, where the sample unit was the individual bird. Percentage data were arcsine square root transformed prior to analysis. Nominal concentrations were used for all estimations.

### D. VERIFICATION OF STATISTICAL RESULTS:

Statistical Method: Analysis was conducted using "chicks.sas" (Ver. 3; March 2002), a SAS program provided by EFED/OPP/USEPA. Data for all endpoints were examined graphically using box plots to determine if they exhibited a dose-dependent response, which was ultimately used to select the multiple comparison test to detect LOAEC and NOAEC. Data for each endpoint were tested to determine if their distributions were normal and if their variances were homogeneous using Shapiro-Wilk's and Levene's tests, respectively. Data that satisfied these assumptions were subjected to Dunnett's and William's tests and data that did not satisfy these assumptions were subjected to the non-parametric MannWhitney-U (with a Bonferroni adjustment) and Jonckheere's tests. Data for dead birds were excluded from the analyses. See Appendix I for output of reviewer's statistical verification and graphs for affected endpoints to support any reviewer-generated conclusions that may differ from those reported in the study.

NOAEC: <65.3 mg ai/kg diet LOAEC: 65.3 mg ai/kg diet

Most sensitive endpoints: adult male body weight gain, the ratios of number hatched to eggs laid and eggs set and the ratio of survivors to eggs set

Table 6: Reproductive and Other Parameters (mean-measured concentrations; reviewer-reported).

Parameter	Control	65.3 mg ai/kg	260 mg ai/kg	1030 mg ai/kg	NOAEC/ LOAEC
Eggs laid/pen	47.1	53.6	49.0	36.0*	260 mg ai/kg 1030 mg ai/kg
Eggs cracked/pen	0.2	0.5	0.3	0.9	1030 mg ai/kg >1030 mg ai/kg
Eggs not cracked/eggs laid (%)	99.6	99.1	99.3	97.5	1030 mg ai/kg >1030 mg ai/kg
Eggs set/pen	42.3	48.1	44.0	30.4*	260 mg ai/kg 1030 mg ai/kg
Shell thickness	0.39	0.40	0.39	0.38	1030 mg ai/kg >1030 mg ai/kg

PMRA Submission Number {.....}

Eggs set/eggs laid (%)	89.8	89.7	89.5	82.3*	260 mg ai/kg 1030 mg ai/kg
Viable embryos/pen	40.3	45.2	42.6	26.7*	260 mg ai/kg 1030 mg ai/kg
Viable embryos/eggs set (%)	95.2	94.1	96.8	88.6	1030 mg ai/kg >1030 mg ai/kg
Live embryos/pen	40.0	45.0	42.2	26.5*	260 mg ai/kg 1030 mg ai/kg
Live embryos/viable embryos (%)	99.5	99.5	99.0	98.8	1030 mg ai/kg >1030 mg ai/kg
No. of hatchlings/pen	33.1	36.1	29.5	20.4*	260 mg ai/kg 1030 mg ai/kg
No. of hatchlings/eggs laid (%)	70.3	66.3*	59.0*	54.0*	<65.3 mg ai/kg 65.3 mg ai/kg
No. of hatchlings/eggs set (%)	78.2	73.9*	65.6*	64.3*	<65.3 mg ai/kg 65.3 mg ai/kg
No. of hatchlings/live embryos (%)	82.6	79.0	68.0	73.0	1030 mg ai/kg >1030 mg ai/kg
Hatchling survival/pen	32.7	35.6	28.9	18.7*	260 mg ai/kg 1030 mg ai/kg
Hatchling survival/eggs set (%)	77.3	72.9*	64.2*	57.7*	<65.3 mg ai/kg 65.3 mg ai/kg
Hatchling survival/no. of hatchlings (%)	98.6	98.6	97.9	86.6*	260 mg ai/kg 1030 mg ai/kg
Hatchling weight (g)	32.2	33.8	31.2	30.7*	260 mg ai/kg 1030 mg ai/kg
Survivor weight (g)	312.5	305.4	301.7	280.6*	260 mg ai/kg 1030 mg ai/kg
Mean food consumption (g/bird/day)	153.7	168.1	175.1	188.2	1030 mg ai/kg >1030 mg ai/kg
Male weight gain (g)	-6.9	-56.1*	-60.4*	-87.3*	<65.3 mg ai/kg 65.3 mg ai/kg
Female weight gain (g)	89.5	59.8	88.5	16.8*	260 mg ai/kg 1030 mg ai/kg

<sup>\*</sup> Statistically different from the control at p<0.05.

PMRA Submission Number {.....}

EPA MRID Number 466955-05

#### E. STUDY DEFICIENCIES:

Treated premixes were prepared every 3 to 4 weeks and were stored frozen in plastic bags until needed; however, frozen storage stability data were not provided. This deficiency affects the scientific soundness of this study. In addition, notable deficiencies from OPPTS 850.2300 guideline included adult birds were younger (21 weeks) at test initiation than recommended (≥28 weeks), and pen floor size was significantly less (3375 cm²/duck) than recommended (at least 10,000 cm²/duck). As cages were much smaller than recommended, documentation that reproductive parameters and health of birds are not adversely affected should have been provided. Furthermore, a NOAEC could not be determined for this study because significant adverse effects on adult and reproductive endpoints were observed at all treated levels. Pre-treatment exposure time was shorter than recommended (8 weeks versus a minimum of 10 weeks).

#### F. REVIEWER=S COMMENTS:

Results of the reviewer's statistical verification were similar to the study author's, in that the mean values were identical. However, the reviewer's conclusions regarding the NOAEC for several affected endpoints differed from those conclusions drawn by the study author. In particular, the reviewer's analysis detected significant adverse effects on overall male body weight gain and relatively-expressed reproductive endpoints (i.e., ratios of number hatched to eggs laid and eggs set and the ratio of survivors to eggs set) which were not detected by the study author. The reviewer's conclusions are reported in the Executive Summary and Conclusions sections.

Based on mean body weights and food consumption, the overall estimated daily dietary dose was calculated as 9.7, 40.2, 181.0 mg ai/kg bw/day for the nominal 63, 250, and 1000 mg ai/kg diet levels, respectively.

Matrix blanks were fortified at 25, 250, or 1200 mg ai/kg diet and analyzed concurrently with sample analysis. Recoveries ranged from 91-109% for all samples (mean range of 100-105%). Sample concentrations were not corrected for mean procedural recoveries.

Samples were analyzed by HPLC/UV. The analytical LOD and LOQ were 10 and 25 mg ai/kg diet, respectively.

In-life dates were May 16 - November 13, 2003.

### **G. CONCLUSIONS:**

This study is scientifically sound; however, freezer storage stability data were not provided and a NOAEC was not determined. In addition, this study does not fulfill guideline requirements because the ducks were younger than required and were maintained in cages significantly smaller than recommended. This study does not fulfill the guideline requirement for an avian reproduction study and is classified as SUPPLEMENTAL.

NOAEC: <65.3 mg ai/kg diet LOAEC: 65.3 mg ai/kg diet

Endpoint(s) Affected: adult male and female weight gain, eggs laid, eggs set, the ratio of eggs set to eggs laid, viable embryos, live embryos, number hatched, the ratios of number hatched to eggs laid and eggs set, 14-day-old survivors, the ratios of survivors to eggs set and number hatched, and hatchling and survivor body weights.

Most sensitive endpoint: adult male body weight gain, the ratios of number hatched to eggs laid and eggs set and the ratio of survivors to eggs set

PMRA Submission Number {.....}

EPA MRID Number 466955-05

#### **E. STUDY DEFICIENCIES:**

Treated premixes were prepared every 3 to 4 weeks and were stored frozen in plastic bags until needed; however, frozen storage stability data were not provided. This deficiency may affect the scientific soundness of this study if inadequate data are provided. In addition, notable deficiencies from OPPTS 850.2300 guideline included adult birds were younger (21 weeks) at test initiation than recommended (≥28 weeks), and pen floor size was significantly less (3375 cm²/duck) than recommended (at least 10,000 cm²/duck). As cages were much smaller than recommended, documentation that reproductive parameters and health of birds are not adversely affected should have been provided. Furthermore, a NOAEC could not be determined for this study because significant adverse effects on adult and reproductive endpoints were observed at all treated levels.

#### F. REVIEWER'S COMMENTS:

Results of the reviewer's statistical verification were similar to the study author's, in that the mean values were identical. However, the reviewer's conclusions regarding the NOAEC for several affected endpoints differed from those conclusions drawn by the study author. In particular, the reviewer's analysis detected significant adverse effects on overall male body weight gain and relatively-expressed reproductive endpoints (i.e., ratios of number hatched to eggs laid and eggs set and the ratio of survivors to eggs set) which were not detected by the study author. The reviewer's conclusions are reported in the Executive Summary and Conclusions sections.

Based on mean body weights and food consumption, the overall estimated daily dietary dose was calculated as 9.7, 40.2, 181.0 mg ai/kg bw/day for the nominal 63, 250, and 1000 mg ai/kg diet levels, respectively.

Matrix blanks were fortified at 25, 250, or 1200 mg ai/kg diet and analyzed concurrently with sample analysis. Recoveries ranged from 91-109% for all samples (mean range of 100-105%). Sample concentrations were not corrected for mean procedural recoveries.

Samples were analyzed by HPLC/UV. The analytical LOD and LOQ were 10 and 25 mg ai/kg diet, respectively.

In-life dates were May 16 – November 13, 2003.

#### G. CONCLUSIONS:

This study is scientifically sound; however, freezer storage stability data were not provided and a NOAEC was not determined. In addition, this study does not fulfill guideline requirements because the ducks were younger than required and were maintained in cages significantly smaller than recommended. This study does not fulfill the guideline requirement for an avian reproduction study and is classified as SUPPLEMENTAL.

NOAEC: <65.3 mg ai/kg diet LOAEC: 65.3 mg ai/kg diet

Endpoint(s) Affected: adult male and female weight gain, eggs laid, eggs set, the ratio of eggs set to eggs laid, viable embryos, live embryos, number hatched, the ratios of number hatched to eggs laid and eggs set, 14-day-old survivors, the ratios of survivors to eggs set and number hatched, and hatchling and survivor body weights.

Most sensitive endpoint: adult male body weight gain, the ratios of number hatched to eggs laid and eggs set and the ratio of survivors to eggs set

PMRA Submission Number {.....}

EPA MRID Number 466955-05

### III. REFERENCES:

- U.S. Environmental Protection Agency. 1982. Pesticide Assessment Guidelines, FIFRA Subdivision E, Hazard Evaluation: Wildlife and Aquatic Organisms, subsection 71-4, Environmental Protection Agency, Office of Pesticide Programs. Washington, DC.
- U.S. Environmental Protection Agency. 1996. Series 850 Ecological Effects Test Guidelines (*draft*), OPPTS Number 850.2300: *Avian Reproduction Test*.
- Organization for Economic Cooperation and Development. 1984. *Avian Reproduction Test*. OECD Guideline for Testing of Chemicals. Guideline 206. Paris.
- American Society of Testing and Materials. 1986. *Standard Practice for Conducting Reproductive Studies with Avian Species*. ASTM Standard E1062-86. Annual Book of ASTM Standards. Vol. 11.04. Philadelphia, PA. 15 pp.
- Merck & Co., Inc. 1991. The Merck Veterinary Manual. Merck & Co., Rahway, NJ. 1832 pp.
- National Research Council. 1996. *Guide for the Care and Use of Laboratory Animals*. Washington, DC. National Academy Press. 125 pp.
- Dunnett, C.W. 1955. A Multiple Comparisons Procedure for Comparing Several Treatments with a Control. *Jour. Amer. Statis. Assoc.* 50: 1096-1121.
- Dunnett, C.W. 1964. New Tables for Multiple Comparisons with a Control. Biometrics 20: 482-491.

PMRA Submission Number {.....}

APPENDIX I. OUTPUT OF REVIEWER'S STATISTICAL VERIFICATION:													
Mallard re				AE01	72	747, MR	ID 46	6955-05					
				L E	S	ES_EL	VE	VE_ES	LE	LE_VE	ИН	NH_EL	
NH_ES 1 Ctrl 78.85	57	0	100.	00	52	91.23	52	100.00	51	98.08	41	71.93	
76.83 2 Ctrl 85.71	61	0	100.	00	56	91.80	54	96.43	53	98.15	48	78.69	
3 Ctrl 82.93	53	2	96.	23	41	77.36	38	92.68	38	100.00	34	64.15	
4 Ctrl 30.77	44	0	100.	00	39	88.64	3.8	97.44	38	100.00	12	27.27	
5 Ctrl 86.21	32	0	100.	00	29	90.63	29	100.00	29	100.00	25	78.13	
6 Ctrl 87.50	18	0	100.	00	16	88.89	15	93.75	15	100.00	14	77.78	
7 Ctrl 89.83	64	0	100.	00	59	92.19	59	100.00	58	98.31	53	82.81	
8 Ctrl 66.67	43	. 0	100.	00	39	90.70	39	100.00	39	100.00	26	60.47	
9 Ctrl 88.89	58	0	100.	00	54	93.10	51	94.44	51	100.00	48	82.76	
10 Ctrl 80.49	45	0	100.	00	41	91.11	40	97.56	39	97.50	33	73.33	
11 Ctrl 94.87	43	0	100.	00	39	90.70	37	94.87	37	100.00	37	86.05	
12 Ctrl 87.80	45	0	100.	00	41	91.11	39	95.12	39	100.00	36	80.00	
13 Ctrl		٠	•		•	•		٠	٠	•	•	•	
14 Ctrl 88.57	39	0	100.	00	35	89.74	34	97.14	34	100.00	31	79.49	
15 Ctrl 76.09	50	0	100.	00	46	92.00	39	84.78	39	100.00	35	70.00	
16 Ctrl 47.92	55	1	98.	18	48	87.27	40	83.33	40	100.00	23	41.82	
17 Dose1 84.62	43	0			39			97.44	38	100.00	33	76.74	
18 Dose1 80.00					30	90.91		93.33	27		24	72.73	
19 Dose1 67.27	60	0	100.	00	55			74.55	41	100.00	37	61.67	
20 Dose1 56.25	35	0			32	91.43	30	93.75	30	100.00	18	51.43	
21 Dosel 77.55	54	0	100.	00	49	90.74	46	93.88	46	100.00	38	70.37	
22 Dose1 47.37	45	2	95.	56	38	84.44	37	97.37	37	100.00	18	40.00	
23 Dose1 73.68	63	1	98.	41	57	90.48	54	94.74	53	98.15	42	66.67	
24 Dosel 66.67					42	91.30	40	95.24	40	100.00	28	60.87	
25 Dosel 78.72	51	. 0			47			95.74	45	100.00	37	72.55	
26 Dose1 86.79	62	3	95.	16	53	85.48	51	96.23	51	100.00	46	74.19	

# Data Evaluation Report on the Reproductive Effects of AE 0172747 Technical on Mallard Duck (Anas platyrhynchos) PMRA Submission Number {....} EPA MRID Number 466955 05

PMRA Subm	ission	Nur	mber {}				····		EPA M	RID N	Number 466955-05
27 Dose1 80.33	66	0	100.00	61	92.42	59	96.72	59	100.00	49	74.24
28 Dose1 63.46	57	0	100.00	52	91.23	51	98.08	50	98.04	33	57.89
29 Dose1 62.79	48	0	100.00	43	89.58	41	95.35	41	100.00	27	56.25
30 Dosel 90.28	82	0	100.00	72	87.80	70	97.22	70	100.00	65	79.27
31 Dose1 84.44	51	1	98.04	45	88.24	44	97.78	44	100.00	38	74.51
32 Dose1 81.48	62	1	98.39	54	87.10	48	88.89	48	100.00	44	70.97
33 Dose2 82.76	62	0	100.00	58	93.55	56	96.55	56	100.00	48	77.42
34 Dose2 73.21	62	0	100.00	56	90.32	54	96.43	53	98.15	41	66.13
35 Dose2 78.79	37	0	100.00	33	89.19	33	100.00	33	100.00	26	70.27
36 Dose2 91.67	53	0	100.00	48	90.57	48	100.00	48	100.00	44	83.02
37 Dose2 51.28	4 4	1	97.73	39	88.64	37	94.87	36	97.30	20	45.45
38 Dose2 79.25	59	0	100.00	53	89.83	51	96.23	51	100.00	42	71.19
39 Dose2 76.92	57	0	100.00	52	91.23	51	98.08	51	100.00	40	70.18
40 Dose2 55.17	34	0	100.00	29	85.29	27	93.10	27	100.00	16	47.06
41 Dose2 82.22	50	1	98.00	45	90.00	45	100.00	44	97.78	37	74.00
42 Dose2 46.94	55	1	98.18	49	89.09	47	95.92	45	95.74	23	41.82
43 Dose2 67.31	56	0	100.00	52	92.86	51	98.08	51	100.00	35	62.50
44 Dose2 0.00	39	1	97.44	33	84.62	32	96.97	32	100.00	0	0.00
45 Dose2 96.97	37	О	100.00	33	89.19	33	100.00	33	100.00	32	86.49
46 Dose2 65.91	48	0	100.00	44	91.67	43	97.73	43	100.00	29	60.42
47 Dose2 16.67	47	0	100.00	42	89.36	38	90.48	37	97.37	7	14.89
	44	1	97.73	38	86.36	36	94.74	35	97.22	32	72.73
	16	0	100.00	11	68.75	10	90.91	10	100.00	4	25.00
	25	3	88.00	18	72.00	18	100.00	18	100.00	13	52.00
51 Dose3		•	•								
52 Dose3 60.00	17	0	100.00	15	88.24	15	100.00	15	100.00	9	52.94
53 Dose3 65.31	53	0	100.00	49	92.45	37	75.51	37	100.00	32	60.38
	46	2	95.65	38	82.61	33	86.84	33	100.00	31	67.39

	A Submi				}	·							EP	A M	RID I	Number 4669	955-05
55 78.0	Dose3	47	0	100.	00	41	87.23	3	8	92.6	8	38	100.	.00	32	68.09	
	Dose3	39	7	82.	05	23	58.97	1	0	43.4	8	9	90.	.00	6	15.38	
57 50.9	Dose3	58	1	98.	28	51	87.93	4	3	84.3	1	41	95.	35	26	44.83	
58 85.1	Dose3	39	0	100.	00	35	89.74	3	2	91.4	3	32	100.	00	30	76.92	
59 67.5	Dose3	46	1	97.	83	40	86.96	3	4	85.0	0	33	97.	06	27	58.70	
72.0			0	100.		43	89.58	4	1	95.3	5	41	100.	00	31	64.58	
83.3			0	100.		12	80.00			00.0		12	100.		10	66.67	
62 66.6				100.		33	89.19			00.0		33	100.		22	59.46	
42.8			0	100.		7	70.00			85.7		6	100.		3	30.00	
64 75.0	Dose3	44	U	100.	00	40	90.91	3	9	97.5	0	39	100.	00	30	68.18	
Mall	lard re	epro	, Ва	ayer	AE01	1727	47, MR	ID	46695	5-05							
	TUOTI											0					
Obs WTGA		NH_]	LE	HS	пì	_E2	HS_	NH	THICK	HAT	M.I.	SUR	∨W'I'	FO	OD	WTGAINM	
1	Ctrl	80	.39	41	78	3.85	100.	00	0.4	0	35	3	41	1	45	-76	148
		90		48			100.		0.3		34		58		76	-27	164
	Ctrl			34		2.93	100.		0.3		33		37	1	53	-34	140
	Ctrl			12		77	100.		0.4		32		93	1	25	-123	75
		86.		25		5.21	100.		0.3		29		60		15		-67
	Ctrl	93.		14		7.50	100.		0.4		34		38		27	126	187
	Ctrl Ctrl	91		53		9.83	100.		0.4		34		07		50	96	234
	Ctrl	94.	.67	26 40		5.67 3.89	100.		0.4		31		11		81	13	29
	Ctrl	84.		48 33		).49	100.		0.3		31		89		43	102	152
	Ctrl	100.		36		2.31	97.		0.3		32		10		22		-164
	Ctrl		.31	35		5.37	97.		0.3		29 35		05		19	59	177
	Ctrl	24.	. JI		0.	/	91	L L			35		46		43	-36	17
	Ctrl	91.	18	30	ΩE	5.71	96.	77	0.3		31		16		1 E		· .
	Ctrl	89.		34		3.91	97.		0.3		31 30		78		45 78	57 -128	-35 219
	Ctrl		50				91.3				3 <b>3</b>		70 98		84	-120 -107	67
	Dose1	86		33		1.62	100.0		0.3		36		15		65	30	133
	Dose1		. 89	23		5.67	95.8		0.4		31		36		61	-94	107
	Dosel	90.		37		.27	100.0		0.3		31		3		41	-119	73
	Dosel	60.		18		5.25	100.0		0.4		36		9		05	-46	-89
21	Dosel	82.		36		3.47	94.		0.3		34		3		85	-86	19
22	Dosel	48.	65	18		.37	100.0		0.3		36		95		49	1	28
	Dosel	79.		41	71	93	97.6		0.43		34		32			-18	75
	Dosel	70.		28	66	6.67	100.0	0 C	0.42		32		38		25	-117	140
	Dose1	82.	22	37	7.8	.72	100.0	0 C	0.38	3 3	33		l 7		49	-85	59
	Dose1	90.		46		.79	100.0		0.40	0 0	37		16		33	18	32
	Dose1	83.		49		.33	100.0		0.43		35	34	10		90	-162	39
	Dose1	66.		33		.46	100.0		0.42		35	29	99		54	-28	159
	Dosel	65.		25		.14	92.5		0.39		30		97		35	3	-44
	Dose1	92.		65		.28	100.0		0.42		34	3.	L 7	15	51	-56	-20
	Dosel	86.		37		.22	97.3		0.43		33	30			69	-185	72
	Dosel	91.		44		.48	100.0		0.39		33		L 5		21	47	174
33	Dose2	85.	/ ⊥	47	81	.03	97.9	92	0.39	9 3	32	28	30	23	37	-117	44

Page 23 of 62

# Data Evaluation Report on the Reproductive Effects of AE 0172747 Technical on Mallard Duck (Anas platyrhynchos) PMRA Submission Number {.....} EPA MRID Number 466955-05

PMI	RA Submis	ssion Numl	oer {	Е	PA MRID N	lumber 466	955-05				
-											
34	Dose2	77.36	40	71.43	97.56	0.39	36	314	160	-43	172
35	Dose2	78.79	26	78.79	100.00	0.37	35	344	229	31	94
36	Dose2	91.67	44	91.67	100.00	0.40	31	289	133	-72	62
37	Dose2	55.56	20	51.28	100.00	0.39	33	300	178	-112	288
38	Dose2	82.35	42	79.25	100.00	0.39	31	288	128	-55	-10
39	Dose2	78.43	40	76.92	100.00	0.40	31	309	179	-159	107
40	Dose2	59.26	15	51.72	93.75	0.41	33	332	139	47	24
41	Dose2	84.09	37	82.22	100.00	0.38	31	332	168	-82	49
42	Dose2	51.11	22	44.90	95.65	0.39	29	288	161	-43	75
43	Dose2	68.63	35	67.31	100.00	0.37	31	313	126	-142	153
44	Dose2	0.00	0	0.00		0.42			141	-66	113
45	Dose2	96.97	30	90.91	93.75	0.36	27	259	138	-130	-154
46	Dose2	67.44	27	61.36	93.10	0.43	30	316	236	-39	118
47	Dose2	18.92	7	16.67	100.00	0.41	27	251	180	-15	77
48	Dose2	91.43	31	81.58	96.88	0.40	31	310	268	30	204
49	Dose3		1	9.09	25.00	0.35	27	249	187	-17	13
50	Dose3	72.22	12	66.67	92.31	0.35	28	262	228	-15	106
51	Dose3	•		, •	•	•		•	•		•
52	Dose3	60.00	9	60.00	100.00	0.41	34	288	130	-115	86
53	Dose3	86.49	30	61.22	93.75	0.37	33	285	146	79	132
54	Dose3	93.94	29	76.32	93.55	0.36	30	281	315	-192	-76
55	Dose3	84.21	30	73.17	93.75	0.41	28	249	156	-18	-82
56	Dose3	66.67	5	21.74	83.33	0.39	34	248	135	-211	-9
57	Dose3	63.41	23	45.10	88.46	0.37	31	292	210	-31	84
58	Dose3	93.75	29	82.86	96.67	0.37	29	302	209	-160	72
59	Dose3	81.82	27	67.50	100.00	0.38	32	308	185	-22	17
60	Dose3	75.61	25	58.14	80.65	0.40	34	292	178	-136	-206
61	Dose3	83.33	10	83.33	100.00	0.40	30	279	199	-102	96
62	Dose3	66.67	21	63.64	95.45	0.38	32	302	201	-165	12
63	Dose3	50.00	2	28.57	66.67	0.39	30	313	163	-159	-57
64	Dose3	76.92	27	67.50	90.00	0.40	29	259	181	<del>-</del> 45	64

PMRA Submission Number {......}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE EL ( Eggs Laid )

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05

Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion

Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Test Stat 0.981	-	-value 0.439	Test Sta 1.596		USE PARAMETRI	C TESTS
	*****	*****	*****	*****	*****	*****
* *						
BASIC SUMMARY	Y STATIS	PICS				
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf.	Interval
Ctrl 15	47.13	11.93	3.08	25.32	40.52,	53.74
Dosel 16	53.63	12.39	3.10	23.10	47.02,	60.23
Dose2 16	49.00	9.21	2.30	18.79	44.09.	53.91
Dose3 15	36.00	15.40	3.98	42.78	27.47,	44.53
Level	Median	Min	Max	%of Control(me	ans)	
%Reduction (me	eans)					
Ctrl	45.00	18.00	64.00			
					•	

Dosel 52.50 33.00 82.00 113.77 -13.77
Dose2 49.00 34.00 62.00 103.96 -3.96
Dose3 39.00 10.00 58.00 76.38 23.62

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
Analysis of Variance (ANOVA) - overall F-test
Numerator df Denominator df F-stat P-value
3 58 5.59 0.002

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean			Williams	Đ 1		Tukey p-	
Dose5		p-value	mean	p-value	Dosel	Dose2	Dose3	Dose4
Ctrl	47.13	•	50.48	•	0.468	0.975	0.077	
Dosel	53.63	0.990	50.48	0.850	•	0.717	0.001	•
Dose2	49.00	0.873	49.00	0.783	•	•	0.025	•
Dose3	36.00	0.022	36.00	0.010	•	•		

SUMMARYNOECLOECDunnettDose2Dose3WilliamsDose2Dose3

PMRA Submission Number {......}

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE NEG EC ( Eggs Cracked ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alphalevel=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.665 <.001 4.087 0.011 USE NON-PARAMETRIC TESTS \* 44 BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval 
 Ctrl
 15
 0.20
 0.56
 0.14

 Dosel
 16
 0.50
 0.89
 0.22

 Dose2
 16
 0.31
 0.48
 0.12

 Dose3
 15
 0.93
 1.91
 0.49
 280.31 0.00, 0.51 178.89 0.02, 0.98 0.06, 0.57 0.00, 1.99 153.19 204.36 Min Max %of Control(means) Median Level %Reduction(means) 
 Ctrl
 0.00
 0.00
 2.00

 Dosel
 0.00
 0.00
 3.00

 Dose2
 0.00
 0.00
 1.00

 Dose3
 0.00
 0.00
 7.00
 250.00 -150.00 156.25 -56.25 466.67 -366.67 \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value 2.06 0.559

MannWhit(Bon) - testing each trt median signif. greater than control Jonckheere - test assumes dose-response relationship, testing positive trend

Level	Median	MannWhit(Bo	on adjust)p	-value	Jonckheere p-value
Ctrl	0.00				•
Dose1	0.00		1.000		0.122
Dose2	0.00		1.000		0.181
Dose3	0.00		1.000		0.112
SUMMARY MannWhi	Lt (Bonf	NOEC adjust) Dose	<u> </u>	LOEC >highest	dose
Jonckhe		Dose	_	>highest	

PMRA Submission Number {.....}

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE ENC EL ((EL-EC)/EL(%))
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analyses.
  Shapiro-Wilks Shapiro-Wilks Levenes Levenes
Test Stat P-value Test Stat P-value
                                                      Levenes Conclusion
                                                                   USE NON-PARAMETRIC
                                          6.655
       0.623
                       <.001
                                                       <.001
TESTS
****************
BASIC SUMMARY STATISTICS

        Level N
        Mean
        StdDev
        StdErr
        Coef of Var
        95% Conf.Interval

        Ctrl 15
        99.63
        1.05
        0.27
        1.05
        99.05, 100.00

        Dosel 16
        99.10
        1.61
        0.40
        1.63
        98.24, 99.96

        Dosel 16
        99.32
        1.06
        0.26
        1.06
        98.75, 99.88

        Dosel 15
        97.45
        5.32
        1.37
        5.45
        94.51, 100.00

              Median
                                        Max %of Control(means)
 Level
                            Min
%Reduction (means)
                         96.23 100.00
95.16 100.00
97.44 100.00
  Ctrl 100.00
                                                       99.47
                                                                                 0.53
  Dose1
               100.00
               100.00
  Dose2
                                                         99.69
                                                                                 0.31
  Dose3
               100.00
                            82.05
                                        100.00
                                                        97.82
                                                                                  2.18
*******************
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
     Kruskal-Wallis test - equality among treatment groups
      Degrees of Freedom TestStat P-value
                                  2.13
                                               0.547
MannWhit (Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
 Level
            Median
                            MannWhit(Bon adjust)p-value Jonckheere p-value
           100.00
  Ctrl
            100.00
                                             1.000
                                                                          0.123
  Dose1
  Dose2
             100.00
                                            1.000
                                                                          0.131
            100.00
  Dose3
                                            1.000
                                                                          0.091
   JMMARYNOECLOECMannWhit (Bonf adjust)Dose3>highest doseJonckheereDose3>highest dose
 SUMMARY
```

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE ES ( Eggs Set )

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05

Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

_	ilks Shap at P	piro-Wilks -value	Levenes Test Sta	Levenes t P-value	Conclusion
0.987	(	0.781	2.337	0.083	USE PARAMETRIC TESTS
*****	*****	******	*****	******	*******
BASIC SUMMA	RY STATIS:	rics			
Level N	Mean	StdDev	StdErr	Coef of Va	r 95% Conf.Interval
Ctrl 15	42.33	11.03	2.85	26.06	36.22, 48.44
Dosel 16	48.06	10.91	2.73	22.70	42.25, 53.88
Dose2 16	44.00	9.11	2.28	20.70	39.15, 48.85
Dose3 15	30.40	14.69	3.79	48.31	22.27, 38.53
Level	Median	Min	Max	%of Control(m	leans)
%Reduction(r	means)	•			
Ctrl	41.00	16.00	59.00		
Dosel	48.00	30.00	72.00	113.53	-13.53
Dose2	44.50	29.00	58.00	103.94	-3.94
Dose3	35.00	7.00	51.00	71.81	28.19
ale	de de de la companya de de la companya de la compa				

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
Analysis of Variance (ANOVA) - overall F-test
Numerator df Denominator df F-stat P-value
3 58 6.60 <.001

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett p-value	Isotonic mean	Williams p-value	Dosel		ukey p-va. Dose3	lues Dose4
Dose5		<u>r</u>		p		20002		20001
Ctrl	42.33	•	45.29		0.518	0.978	0.032	٠
Dose1	48.06	0.987	45.29	0.840	•	0.753	<.001	•
Dose2	44.00	0.869	44.00	0.776	•	•	0.009	
Dose3	30.40	0.009	30.40	0.004			•	

SUMMARY NOEC LOEC

Dunnett Dose2 Dose3

Williams Dose2 Dose3

Data Evaluation Report on the Reprodu	uctive Effects of	AE 0172747 Technic	al on Mallard
Duck (Anas platyrhynchos)			

PMRA Submission Number {.....}

PMRA Submission Number {.....}

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE ES EL ( EggsSet/EggsLaid (%) )
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analvses.
 Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion
   Test Stat P-value Test Stat P-value
     0.847
                 <.001
                              14.276
                                        <.001
                                                USE NON-PARAMETRIC
TESTS
*******************************
BASIC SUMMARY STATISTICS
Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval
 Ctrl 15 89.76 3.75 0.97
Dosel 16 89.73 2.41 0.60
Dose2 16 89.48 2.45 0.61
Dose3 15 82.30 10.13 2.62
                                       4.17
                                                     87.69, 91.84
                                         2.69
2.74
                                                      88.44,
                                                              91.02
                                                      88.18, 90.79
                                         12.31
                                                      76.69. 87.91
Level Median Min Max %of Control(means)
%Reduction(means)
 Ctrl 90.70 77.36 93.10
Dose1 90.72 84.44 92.42
           90.72 84.44
                                        99.96
                                                           0.04
 Dose2
           89.60 84.62
                             93.55
                                         99.69
                                                           0.31
 Dose3
           87.23 58.97
                             92.45
                                         91.69
                                                           8.31
******************************
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
   Kruskal-Wallis test - equality among treatment groups
    Degrees of Freedom TestStat P-value
                        11.20
MannWhit (Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
Level
        Median
                   MannWhit(Bon adjust)p-value Jonckheere p-value
         90.70
 Ctrl
         90.72
 Dosel
                                1.000
                                                      0.339
 Dose2
         89.60
                                0.428
                                                      0.135
 Dose3
         87.23
                                0.011
                                                      < .001
SUMMARY
                         NOEC
                                       LOEC
  MannWhit (Bonf adjust) Dose2

Jonckheere Dose2
                                        Dose3
                                        Dose3
```

PMRA Submission Number {......}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE VE ( Viable Embryo(d14) ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alphalevel=0.05Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes
Test Stat P-value Test Stat P-value

1.977 0.127 Levenes Conclusion USE PARAMETRIC TESTS \*\*\*\*\*\*\*\*\*\*\*\*\*\*\* BASIC SUMMARY STATISTICS 
 Level N
 Mean
 StdDev
 StdErr
 Coef of Var
 95% Conf.Interval

 Ctrl 15
 40.27
 10.77
 2.78
 26.74
 34.30, 46.23

 Dosel 16
 45.19
 10.55
 2.64
 23.34
 39.57, 50.81

 Dose2 16
 42.63
 8.99
 2.25
 21.09
 37.84, 47.41

 Dose3 15
 26.73
 13.18
 3.40
 49.29
 19.44, 34.03
 Min Median Max %of Control(means) Level %Reduction(means) Ctrl 39.00 15.00 59.00 .

Dosel 44.50 28.00 70.00 112.22

Dose2 44.00 27.00 56.00 105.86

Dose3 33.00 6.00 43.00 66.39 -12,22 -5.86 33.61 \*\*\*\*\*\*\*\*\*\*\*\*\*\* ++ PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 58 8.65 Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend

Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett p-value	Isotonic mean	Williams p-value	Dosel		Tukey p-v Dose3	values Dose4
Dose5		1		ī				
Ctrl	40.27		42.81		0.597	0.932	0.007	
Dosel	45.19	0.981	42.81	0.821		0.911	<.001	•
Dose2	42.63	0.911	42.63	0.839	•		<.001	•
Dose3	26.73	0.002	26.73	<.001	•			•
•								

SUMMARY NOEC LOEC Dunnett Dose2 Dose3 Williams Dose2 Dose3

### Data Evaluation Report on the Reproductive Effects of AE 0172747 Technical on Mallard Duck (Anas platyrhynchos) PMRA Submission Number {.....}

PMRA Submission Number {.....}

SUMMARY

Jonckheere

EPA MRID Number 466955-05

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE VE ES ( ViableEmbryo/EggsSet (%) )
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analyses.
 Shapiro-Wilks Shapiro-Wilks
                            Levenes
                                       Levenes
                                              Conclusion
   Test Stat P-value
                           Test Stat P-value
     0.713
                < .001
                              4.512
                                       0.007
                                               USE NON-PARAMETRIC
TESTS
************
* *
BASIC SUMMARY STATISTICS
Level N Mean StdDev
                            StdErr Coef of Var
                                                   95% Conf.Interval
                                     5.38
                            1.32
 Ctrl 15
                  5.12
                                                     92.34,
         95.17
 Dosel 16 94.14 5.71 1.43
Dosel 16 96.82 2.68 0.67
Dosel 15 88.58 14.45 3.73
                                       6.06
                                                     91.10,
                                                             97.18
                                        2.77
                                                    95.39,
                                                            98.25
                             3.73
                                       16.32
                                                    80.58.
                                                           96.59
                   Min
Level
          Median
                            Max %of Control(means)
%Reduction(means)
                 83.33 100.00
       96.43
 Ctrl
                                       98.92
                                                         1.08
 Dose1
           95.55 74.55
                            98.08
 Dose2
           96.76
                  90.48
                           100.00
                                      101.74
                                                        -1.74
 Dose3
           91.43 43.48
                           100.00
                                        93.08
                                                         6.92
***********
* *
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
   Kruskal-Wallis test - equality among treatment groups
    Degrees of Freedom TestStat P-value
                         5.03
                                 0.170
MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
Level
        Median
                    MannWhit(Bon adjust)p-value Jonckheere p-value
 Ctrl
        96.43
         95.55
                               0.778
                                                    0.251
 Dosel
 Dose2
         96.76
                               1.000
                                                    0.821
 Dose3
         91.43
                               0.340
                                                    0.246
```

NOEC

Dose3

MannWhit (Bonf adjust) Dose3

LOEC

>highest dose

>highest dose

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE LE ( Live Embryo(d21) ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance (absolute residuals) -- alphalevel=0.05Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.989 0.833 2.049 0.117 USE PARAMETRIC TESTS \* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval Ctrl 15 40.00 10.48 2.71 26.20 34.20, 45.80 39.37, Dose1 16 45.00 10.57 2.64 23.49 50.63 Dose2 16 42.19 8.97 Dose3 15 26.47 13.07 2.24 3.37 37.41, 21.26 46.97 49.36 19.23, 33.70 Level Median Min Max %of Control(means) %Reduction(means) 39.00 15.00 58.00 . 44.50 27.00 70.00 112.50 43.50 27.00 56.00 105.47 33.00 6.00 41.00 66.17 Ctrl 39.00 -12.50 Dose1 -5.47 Dose2 Dose3 33.83 \* \* \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 3 58 8.80 <.001 Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC L

Level	Mean	Dunnett p-value	Isotonic mean	Williams p-value	Dose1		Tukey p-v Dose3	
Dose5		p varue	modri	p varue	20001	50302	50303	D0364
Ctrl	40.00	•	42.58	•	0.577	0.943	0.006	•
Dose1	45.00	0.983	42.58	0.826	٠	0.883	<.001	
Dose2	42.19	0.904	42.19	0.828	٠		<.001	
Dose3	26.47	0.002	26.47	<.001	•	•	•	•

SUMMARY	NOEC	LOEC	
Dunnett	Dose2	Dose3	
Williams	Dose2	Dose3	

PMRA Submission Number {.....}

PMRA Submission Number {.....}

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE LE VE ( LiveEmbryo/ViableEmbryo (%) )
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance (absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analyses.
  Shapiro-Wilks Shapiro-Wilks
                                    Levenes
                                                 Levenes Conclusion
    Test Stat P-value Test Stat P-value
      0.662
                    <.001
                                     3.417
                                                 0.023 USE NON-PARAMETRIC
TESTS
***********
BASIC SUMMARY STATISTICS
 Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval

      Ctrl
      15
      99.47
      0.93
      0.24
      0.93

      Dosel
      16
      99.54
      1.05
      0.26
      1.06

      Dosel
      16
      98.97
      1.45
      0.36
      1.46

      Dosel
      15
      98.83
      2.80
      0.72
      2.83

                                                                  98.96, 99.98
                                                                   98.98, 100.00
                                                                   98.20, 99.74
                                                                  97.28, 100.00
 Level Median Min Max %of Control(means)
%Reduction(means)

      Ctrl
      100.00
      97.50
      100.00

      Dosel
      100.00
      96.43
      100.00

      Dose2
      100.00
      95.74
      100.00

                                               100.07
                                                                       -0.07
                                                 99.50
                                                                        0.50
  Dose3
             100.00 90.00
                                   100.00
                                                  99.36
                                                                        0.64
*******************************
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
    Kruskal-Wallis test - equality among treatment groups
     Degrees of Freedom TestStat P-value
                               1.78
                                          0.620
MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
Level
          Median
                         MannWhit(Bon adjust)p-value Jonckheere p-value
          100.00
  Ctrl
          100.00
  Dosel
                                       1.000
                                                                  0.647
  Dose2
          100.00
                                       1.000
                                                                  0.155
 Dose3 100.00
                                       1.000
                                                                  0.303
 SUMMARY
                              NOEC
                                               LOEC
  MannWhit (Bonf adjust) Dose3
Jonokheere Dose3
                                                >highest dose
                                                 >highest dose
```

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE NH ( Number Hatched ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.983 0.556 0.264 0.851 USE PARAMETRIC TESTS \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* \* \* BASIC SUMMARY STATISTICS StdErr Coef of Var 95% Conf.Interval Level N Mean StdDev 3.06 35.81 Ctrl 15 33.07 11.84 26.51, 39.62 Dosel 16 36.06 12.04 3.01 33.39 29.65, 42.48 Dose2 16 29.50 13.55 Dose3 15 20.40 11.43 22.28, 3.39 45.93 36.72 2.95 56.01 14.07, 26.73 Min Level Median Max %of Control(means) %Reduction(means) Ctrl 34.00 12.00 53.00 Dosel 37.00 18.00 65.00 109.06 -9.06 48.00 0.00 Dose2 32.00 89.21 10.79 26.00 3.00 32.00 61.69 \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* \* \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 3 58 4.69 0.005 Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

_			•	•	•				
Level	Mean	Dunnett p-value	Isotonic mean	Williams p-value			Tukey p-		
Dose5		b-varde	mean	b-varue	Doser	Dosez	DOSES	DOSE4	
Ctrl	33.07	•	34.61	•	0.904	0.850	0.032		
Dose1	36.06	0.925	34.61	0.724	•	0.436	0.004	•	
Dose2	29.50	0.402	29.50	0.270	•	•	0.177	•	
Dose3	20.40	0.009	20.40	0.004	•	•			
SUMMARY Dunne <b>Willi</b>	ett		NOEC Dose <b>Dose</b>		LOEC Dose3 <b>Dose3</b>				

Data Evaluatio	n Report on t	the Reproductive	Effects of	f AE 017274'	7 Technical o	n Mallard
Duck (Anas pla	tvrhvnchos)					

PMRA Submission Number {.....}

PMRA Submission Number {.....}

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE NH EL ( NumberHatched/EggsLaid (%) )
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analyses.
 Shapiro-Wilks Shapiro-Wilks
                            Levenes
                                     Levenes
                                              Conclusion
   Test Stat P-value
                           Test Stat P-value
                <.001
     0.878
                             2.095
                                     0.111
                                              USE NON-PARAMETRIC
TESTS
*************************
BASIC SUMMARY STATISTICS
Level N Mean StdDev
                           StdErr Coef of Var
                                                  95% Conf.Interval
                 16.33
 Ctrl 15
                           4.22
           70.31
                                    23.23
                                                  61.27, 79.36
 Dosel 16 66.27
                  10.72
                            2.68
                                      16.18
                                                   60.56,
                                                           71.99
 Dose2 16 58.97 23.94
Dose3 15 54.03 17.86
                            5.99
                                      40.60
                                                   46.21, 71.73
                            4.61
                                      33.06
                                                   44.14, 63.93
Level Median Min Max %of Control(means)
%Reduction(means)
                 27.27 86.05
 Ctrl 77.78
                 40.00
           70.67
                                                       5.74
 Dose1
                            79.27
                                      94.26
 Dose2
          68.15
                   0.00
                           86.49
                                      83.87
                                                       16.13
 Dose3
          59.46 15.38
                            76.92
                                      76.85
                                                       23.15
*************************
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
   Kruskal-Wallis test - equality among treatment groups
    Degrees of Freedom TestStat P-value
                       10.64
                                0.014
MannWhit (Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
```

Level	Median	MannWhit(Bon	adjust)p.	-value	Jonckheere p-value
Ctrl	77.78				
Dosel	70.67		0.155		0.045
Dose2	68.15		0.173		0.023
Dose3	59.46		0.009		<.001
SUMMARY MannWhi <b>Jonckhe</b>	t (Bonf ad] ere	-	st dose	LOEC Dose3 <b>Dose1</b>	

PMRA Submission Number {.....}

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE NH ES ( NumberHatched/EggsSet (%) )
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analyses.
  Shapiro-Wilks Shapiro-Wilks
                                    Levenes Levenes Conclusion
    Test Stat P-value Test Stat P-value
       0.887
                     <.001
                                                   0.135 USE NON-PARAMETRIC
                                      1.926
TESTS
*************************
BASIC SUMMARY STATISTICS

        Level N
        Mean
        StdDev
        StdErr
        Coef of Var

        Ctrl 15
        78.21
        17.46
        4.51
        22.32

        Dosel 16
        73.86
        12.05
        3.01
        16.31

        Dose2 16
        65.58
        26.44
        6.61
        40.32

        Dose3 15
        64.25
        17.85
        4.61
        27.78

                                                                  95% Conf.Interval
                                                                  68.54, 87.87
                                                                   67.44,
                                                                            80.28
                                                                   51.49, 79.67
                                                                   54.37, 74.13
Level Median Min Max %of Control(means)
%Reduction(means)
  Ctrl 85.71 30.77 94.87
Dosel 78.14 47.37 90.28
Dose2 75.07 0.00 96.97
                                                  94.44
                                                                         5.56
                                                  83.86
                                                                         16.14
  Dose3
              67.50
                        26.09
                                    85.71
                                                   82.16
                                                                         17.84
********************************
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
    Kruskal-Wallis test - equality among treatment groups
     Degrees of Freedom TestStat P-value
                               8.37
                                           0.039
MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
          Median
 Level
                        MannWhit(Bon adjust)p-value Jonckheere p-value
          85.71
  Ctrl
            78.14
75.07
  Dosel
                                        0.149
                                                                   0.043
                                                                   0.019
  Dose2
                                        0.123
         67.50
  Dose3
                                        0.017
                                                                   0.002
                               NOEC
                                                 LOEC
   MannWhit (Bonf adjust) Dose2
                                                  Dose3
   Jonckheere
                                 <lowest dose Dose1</pre>
```

PMRA Submission Number {.....}

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE NH LE ( NumberHatched/LiveEmbryo (%) )
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analyses.
  Shapiro-Wilks Shapiro-Wilks
                                   Levenes
                                               Levenes Conclusion
    Test Stat P-value
                                   Test Stat P-value
     0.876
                    < .001
                                   1.671
                                                0.183 USE NON-PARAMETRIC
TESTS
*************************
BASIC SUMMARY STATISTICS
                               StdErr Coef of Var
 Level N Mean StdDev
                                                            95% Conf.Interval

    Ctrl
    15
    82.60
    17.86
    4.61
    21.62

    Dosel
    16
    79.04
    13.07
    3.27
    16.54

    Dosel
    16
    67.98
    26.57
    6.64
    39.08

    Dosel
    15
    73.00
    15.45
    3.99
    21.17

                                                               72.71, 92.49
                                                                 72.08,
                                                                          86.01
                                                                53.82, 82.14
                                                                 64.45, 81.56
Level Median Min Max %of Control (means)
%Reduction(means)

      Ctrl
      89.74
      31.58
      100.00

      Dosel
      82.83
      48.65
      92.86

      Dose2
      77.89
      0.00
      96.97

                                                 95.69
                                                                      4.31
                                                82.30
                                                                      17.70
              75.61
  Dose3
                       40.00
                                   93.94
                                                 88.38
                                                                      11.62
*************************
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
    Kruskal-Wallis test - equality among treatment groups
     Degrees of Freedom TestStat P-value
                               6.54
                                         0.088
MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
         Median
Level
                        MannWhit(Bon adjust)p-value Jonckheere p-value
          89.74
  Ctrl
  Dose1
            82.83
                                      0.223
                                                                0.067
            77.89
  Dose2
                                      0.076
                                                                0.008
  Dose3
            75.61
                                      0.084
                                                                0.007
                                               LOEC
                               NOEC
                             Dose3
  MannWhit (Bonf adjust)
                                               >highest dose
   Jonckheere
                               Dose1
                                                Dose2
```

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE HS ( Hatching Survival(d14) ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alphalevel=0.05Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.985 0.671 0.888 USE PARAMETRIC TESTS 0.211 \* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval Ctrl 15 32.67 11.94
Dosel 16 35.63 12.16
Dose2 16 28.94 13.49
Dose3 15 18.67 10.90 3.08 36.55 26.06, 39.28 34.15 3.04 29.14, 42.11 3.37 46.61 21.75, 36.12 2.81 58.39 12.63, 24.70 Level Median Min Max %of Control(means) %Reduction(means) 12.00 •53.00 18.00 65.00 Ctrl 34.00 36.50 Dose1 109.06 -9.06 0.00 30.50 Dose2 88.58 47.00 11.42 23.00 1.00 30.00 57.14 Dose3 42.86 \* \* \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 5.63 0.002

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	-	Isotonic mean	Williams p-value	Dose1	Dose2	Tukey p-v	alues Dose4
Dose5		p varue	mean	p value	DOSEI	DOSEZ	Doses	Doseq
Ctrl	32.67	•	34.19	•	0.906	0.829	0.013	
Dosel	35.63	0.924	34.19	0.724	•	0.413	0.002	
Dose2	28.94	0.384	28.94	0.254		•	0.100	
Dose3	18.67	0.004	18.67	0.001	٠	•	•	•
SUMMARY Dunnet Willia			NOEC Dose: <b>Dose</b> :		LOEC Dose3 <b>Dose3</b>			

PMRA Submission Number {.....}

PMRA Submission Number {.....}

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE HS ES ( HatchingSurvival/EggsSet (%) )
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analyses.
  Shapiro-Wilks Shapiro-Wilks
                                 Levenes Levenes Conclusion
    Test Stat P-value Test Stat P-value
     0.879
                   <.001
                                 2.014 0.122 USE NON-PARAMETRIC
TESTS
*******************************
BASIC SUMMARY STATISTICS
 Level N Mean StdDev StdErr Coef of Var
                                                            95% Conf.Interval

      Ctrl
      15
      77.26
      17.66
      4.56

      Dosel
      16
      72.85
      12.12
      3.03

      Dose2
      16
      64.19
      25.98
      6.50

      Dose3
      15
      57.66
      22.14
      5.72

                                 4.56 22.86
                                                            67.48, 87.04
                                              16.64
                                                             66.40,
                                                                       79.31
                                            40.48
                                                             50.35, 78.03
                                              38.41
                                                              45.39, 69.92
Level Median Min Max %of Control (means)
%Reduction(means)
 Ctrl 85.37 30.77 92.31
Dosel 75.07 47.37 90.28
Dose2 74.18 0.00 91.67
Dose3 63.64 9.09 83.33
                                              94.30
                                                                   5.70
                                              83.08
                                                                  16.92
                                              74.63
                                                                   25.37
**************************
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
    Kruskal-Wallis test - equality among treatment groups
     Degrees of Freedom TestStat P-value
                           10.53
                                       0.015
MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
         Median
Level
                      MannWhit(Bon adjust)p-value Jonckheere p-value
         85.37
  Ctrl
  Dosel
           75.07
                                    0.149
                                                             0.043
           74.18
  Dose2
                                    0.114
                                                             0.020
 Dose3
          63.64
                                    0.007
                                                             <.001
                            NOEC
SUMMARY
                                            LOEC
  MannWhit (Bonf adjust) Dose2
                                             Dose3
   Jonckheere
                              <lowest dose Dose1</pre>
```

PMRA Submission Number {.....}

```
Mallard repro, Bayer AE0172747, MRID 466955-05
ANALYSIS RESULTS FOR VARIABLE HS NH ( HatchingSurvival/NumberHatched (%) )
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-
level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric
analyses.
  Shapiro-Wilks Shapiro-Wilks
                               Levenes Levenes
                                                     Conclusion
    Test Stat P-value Test Stat P-value
     0.547
                  <.001
                                 7.311
                                           <.001
                                                    USE NON-PARAMETRIC
TESTS
*************************
BASIC SUMMARY STATISTICS
 Level N Mean StdDev
                               StdErr
                                         Coef of Var
                                                         95% Conf.Interval
                   2.42
            98.65
                               0.62
 Ctrl 15
                                         2.45
                                                         97.31, 99.99
 Dosel 16 98.63 2.35
Dose2 15 97.91 2.66
Dose3 15 86.64 19.19
                                0.59
                                                          97.38,
                                            2.38
                                                                   99.89
                                0.69
                                            2.72
                                                          96.43, 99.38
                                4.95
                                           22.15
                                                          76.01, 97.26
Level Median Min Max % of Control (means)
%Reduction(means)

      Ctrl
      100.00
      91.30
      100.00

      Dosel
      100.00
      92.59
      100.00

      Dose2
      100.00
      93.10
      100.00

                                            99.98
                                                               0.02
                                           99.25
                                                               0.75
 Dose3
            93.55
                   25.00
                               100.00
                                           87.83
                                                              12.17
********************************
NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
   Kruskal-Wallis test - equality among treatment groups
    Degrees of Freedom TestStat P-value
                          17.15
                                     <.001
MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend
Level
        Median
                      MannWhit (Bon adjust) p-value Jonckheere p-value
         100.00
 Ctrl
 Dose1
         100.00
                                  1.000
                                                         0.557
 Dose2
         100.00
                                  1.000
                                                         0.224
 Dose3
          93.55
                                  0.004
                                                         < .001
 SUMMARY
                          NOEC
                                          LOEC
                         Dose2
  MannWhit (Bonf adjust)
                                           Dose3
  Jonckheere
                           Dose2
                                           Dose3
```

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE THICK ( Eggshell thickness ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alphalevel=0.05Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.507 0.982 0.467 0.706 USE PARAMETRIC TESTS \* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval Ctrl 15 0.39 0.02 0.01 4.96 0.38, 0.41 Dosel 16 0.40 0.02 0.01 5.29 0.39, 0.41 Dose2 16 0.39 0.02 0.00 4.79 0.38, 0.40 Dose3 15 0.38 0.02 0.01 5.46 0.37, 0.39 Level Median Min Max %of Control(means) %Reduction(means) 
 Ctrl
 0.39
 0.36
 0.43

 Dosel
 0.40
 0.36
 0.44
 100.71

 Dose2
 0.39
 0.36
 0.43
 99.77

 Dose3
 0.38
 0.35
 0.41
 96.72
 -0.710.23 \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 1.83 0.152

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett	Isotonic	Williams	D 1		Tukey p-v	
Dose5		p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4
Ctrl	0.39		0.40		0.980	0.999	0.301	
Dosel	0.40	0.865	0.40	0.666		0.954	0.142	•
Dose2	0.39	0.700	0.39	0.562	•	•	0.350	•
Dose3	0.38	0.099	0.38	0.052	•	•	•	
SUMMARY Dunne Willi	tt		NOEC Dose Dose		LOEC >highes >highes			

PMRA Submission Number {.....}

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE HATWT ( Hatchling Weight ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alphalevel=0.05Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.981 0.461 0.209 0.889 USE PARAMETRIC TESTS \* \* \* BASIC SUMMARY STATISTICS 
 Level N
 Mean
 StdDev
 StdErr
 Coef of Var
 95% Conf.Interval

 Ctrl 15
 32.20
 2.01
 0.52
 6.23
 31.09, 33.31

 Dosel 16
 33.75
 2.05
 0.51
 6.07
 32.66, 34.84

 Dose2 15
 31.20
 2.48
 0.64
 7.96
 29.82, 32.58

 Dose3 15
 30.73
 2.34
 0.61
 7.63
 29.44, 32.03
 Level Median Min Max %of Control(means) %Reduction(means) 
 Ctrl
 32.00
 29.00
 35.00

 Dosel
 34.00
 30.00
 37.00
 104.81

 Dose2
 31.00
 27.00
 36.00
 96.89

 Dose3
 30.00
 27.00
 34.00
 95.45
 -4.81 3.11 4.55 \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 3 5.60 0.002 Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett p-value	Isotonic mean	Williams p-value	Dose1	Dose2	Tukey p-v Dose3	values Dose4
Dose5		p varae	mean	b varue	DOSEI	DOSEZ	Doses	DOSE4
Ctrl	32.20	•	33.00	•	0.225	0.611	0.282	
Dose1	33.75	0.998	33.00	0.905		0.012	0.002	•
Dose2	31.20	0.239	31.20	0.142	•		0.939	
Dose3	30.73	0.092	30.73	0.048	•	•		٠
SUMMARY Dunne <b>W</b> illi	tt		NOEC Dose <b>Dose</b>	=	LOEC >highes <b>Dose3</b>	st dose		

### Data Evaluation Report on the Reproductive Effects of AE 0172747 Technical on Mallard Duck (Anas platyrhynchos) PMRA Submission Number {.....}

PMRA Submission Number {.....}

EPA MRID Number 466955-05

0.070

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE SURVWT ( Survivor Wt (d14) ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alphalevel=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.987 0.739 1.994 0.125 USE PARAMETRIC TESTS \* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval Ctrl 15 312.47 27.32 7.05 8.74 297.34, 327.60 Dosel 16 305.44 14.68 3.67 4.81 297.61, 313.26 Dose2 15 301.67 26.23 6.77 8.70 287.14, 316.19 Dose3 15 280.60 22.24 5.74 7.93 268.28, 292.92 Level Median Min Max %of Control(means) %Reduction(means) Ctrl 310.00 260.00 358.00 Dosel 304.00 282.00 340.00 Dose2 309.00 251.00 344.00 Dose3 285.00 248.00 313.00 97.75 96.54 2.25 3.46 89.80 10.20 \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value - 3 57 5.33 0.003 Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC Dunnett Isotonic Williams Level Mean Tukey p-values mean p-value Dose1 Dose2 Dose3 Dose4 p-value Dose5 Ctrl 312.47 . 312.47 . 0.831 0.577 0.002 Dosel 305.44 0.386 305.44 0.239 . 0.968 0.020

Will	iams		Dose2	Dose3	
Dunn			Dose2	2	Dose3
SUMMAR	Y		NOEC		LOEC
Dose3	280.60	<.001	280.60	<.001	•
•					
Dose2	301.67	0.221	301.67	0.129	

PMRA Submission Number {......}

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE FOOD (Food Consumption) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance (absolute residuals) -- alphalevel=0.05Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Conclusion Test Stat P-value Test Stat P-value 0.949 0.012 0.851 0.472 USE PARAMETRIC TESTS \* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval Ctrl 15 153.73 28.60 7.38 18.60 137.90, 169.57 Dosel 16 168.13 32.49 8.12 19.32 150.81, 185.44 Dose2 16 175.06 44.61 11.15 25.48 151.29, 198.83 Dose3 15 188.20 45.27 11.69 24.05 163.13, 213.27 Level Median Min Max %of Control(means) %Reduction(means) 
 Ctrl
 145.00
 115.00
 219.00

 Dosel
 163.00
 105.00
 225.00
 109.36

 Dose2
 164.50
 126.00
 268.00
 113.87

 Dose3
 185.00
 130.00
 315.00
 122.42
 -9.36 -13.87 \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 3 2.10 0.111 Dunnett - testing each trt mean signif. less than control

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett p-value	Isotonic mean	Williams p-value	Dose1	Dose2	Tukey p-v	values Dose4
Dose5		P		p varao	20001	20002	20203	20201
Ctrl	153.73	•	171.29	•	0.726	0.419	0.078	•
Dosel	168.13	0.967	171.29	0.946	•	0.956	0.473	•
Dose2	175.06	0.992	171.29	0.960	•	•	0.778	•
Dose3	188.20	1.000	171.29	0.966		•		•
SUMMAR Dunn Will	ett		NOEC Dose Dose		LOEC >highes >highes			

### Data Evaluation Report on the Reproductive Effects of AE 0172747 Technical on Mallard **Duck** (*Anas platyrhynchos*) PMRA Submission Number {.....}

PMRA Submission Number {.....}

SUMMARY

Dunnett

Williams

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE WTGAINM ( Male wt gain ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alphalevel=0.05Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.973 0.179 1.474 0.231 USE PARAMETRIC TESTS \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* \*\* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval Ctrl 15 -6.93 84.51 21.82 -1218.86 -53.73, 39.87 Dosel 16 -56.06 68.94 17.24 -122.97 -92.80, -19.33 Dose2 16 -60.44 62.68 15.67 -103.72 -93.84, -27.04 Dose3 15 -87.27 83.64 21.60 -95.84 -133.58, -40.95 Level Median Min Max %of Control(means) %Reduction(means) 

 Ctrl
 -27.00
 -128.00
 126.00
 .

 Dose1
 -51.00
 -185.00
 47.00
 808.59

 Dose2
 -60.50
 -159.00
 47.00
 871.69

 Dose3
 -102.00
 -211.00
 79.00
 1258.65

 -708.59 -771.69 -1158.65\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* \* \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat 3 0.039 58 2.97 Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC Level Mean Dunnett Isotonic Williams Tukey p-values mean p-value Dosel Dose2 p-value Dose3 Dose4 Dose5 Ctrl -6.93 . -6.93 . 0.276 0.208 0.025 Dose1 -56.06 0.089 -56.06 0.043 . 0.998 0.658 Dose2 -60.44 0.065 -60.44 0.032 0.754 Dose3 -87.27 0.007 -87.27 0.003 .

<lowest dose Dose1</pre>

LOEC

Dose3

NOEC

Dose2

PMRA Submission Number {......}

PMRA Submission Number {.....}

EPA MRID Number 466955-05

Mallard repro, Bayer AE0172747, MRID 466955-05 ANALYSIS RESULTS FOR VARIABLE WTGAINF ( Female wt gain ) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alphalevel=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.080 1.126 0.346 USE PARAMETRIC TESTS 0.966 \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval Ctrl 15 89.53 114.68 29.61 128.09 26.02, 153.04 Dosel 16 59.81 73.31 18.33 122.57 20.75, 98.88 Dose2 16 88.50 97.76 24.44 110.46 36.41, 140.59 Dose3 15 16.80 91.12 23.53 542.39 -33.66, 67.26 Level Median Min Max %of Control(means) %Reduction(means) 
 Ctrl
 140.00
 -164.00
 234.00


 Dosel
 65.50
 -89.00
 174.00

 Dose2
 85.50
 -154.00
 288.00


 Dose3
 17.00
 -206.00
 132.00
 66.80 33.20 98.85 1.15 18.76 81.24 \* \* \* PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 3 58 1.96 0.130 Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC Level Mean Dunnett Isotonic Williams Tukev p-values

SUMMARY Dunnet Willia	tt		NOEC Dose <b>Dose</b> :		LOEC >highes <b>Dose3</b>	st dose		
	10.00	0.031	10.00	0.025	•	•	•	•
Dose3	16.80	0.051	16.80	0.025				
Dose2	88.50	0.736	74.16	0.416	•		0.166	
Dosel	59.81	0.376	74.16	0.389		0.829	0.593	
Ctrl	89.53		89.53		0.820	1.000	0.167	•
Dose5		p varae	mean	p varue		00302	Doses	DOSE4
Te AeT	mean	p-value	mean	p-value	Dose1		Tukey p-1 Dose3	Dose4


#### **Box Plot:**




Mallard repro, Bayer AE0172747, MRID 466955-05





Mallard repro, Bayer AE0172747, MRID 466955-05







### Mallard repro, Bayer AE0172747, MRID 466955-05










#### Mallard repro, Bayer AE0172747, MRID 466955-05









#### Mallard repro, Bayer AE0172747, MRID 466955-05







### Mallard repro, Bayer AE0172747, MRID 466955-05

